Use of very old and very new antibiotics in intensive care units in Germany.

1. Clotet B, Bellos N, Molina JM et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169–78. 2. De Meyer S, Vangeneugden T, Lefebvre E et al. Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3. In: Abstracts of the Fifteenth International HIV Drug Resistance Workshop, Sitges, Spain, 2006. Abstract 73. 3. Johnson V, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14: 125–30. 4. Hertogs K, de Bethune M, Miller V et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant HIV type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42: 269–76. 5. Cohen C, Falcon R, Rinehart A et al. Factors influencing darunavir/r efficacy in treatment-experienced HIV patients. POWER 1, 2 and 3 pooled 48-week analysis. In: Abstracts of the Forty-fourth IDSA, Toronto, Canada, 2006. Abstract P688.